Indications for OXBRYTA:
Sickle cell disease in patients aged ≥12yrs.
Swallow whole. 1500mg once daily. Severe hepatic impairment: 1000mg once daily. Avoid concomitant strong CYP3A4 inhibitors or fluconazole; if unavoidable, reduce dose to: 1000mg once daily. Avoid concomitant strong or moderate CYP3A4 inducers; if unavoidable, increase dose to: 2500mg once daily.
<12yrs: not established.
Severe hepatic impairment: reduce dose (see Adults). Pregnancy. Nursing mothers: not recommended (during and for ≥2 weeks after the last dose).
Hemoglobin S polymerization inhibitor.
May be potentiated by strong CYP3A4 inhibitors or fluconazole; reduce voxelotor dose (see Adults). May be antagonized by strong or moderate CYP3A4 inducers; increase voxelotor dose (see Adults). Avoid concomitant sensitive CYP3A4 substrates with a narrow therapeutic index; if unavoidable, consider dose reduction of the substrate. May interfere with measurement of Hb subtypes by high-performance liquid chromatography.
Headache, diarrhea, abdominal pain, nausea, fatigue, rash, pyrexia; hypersensitivity reactions (discontinue if occur).
Generic Drug Availability: